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Abstract
Following current recommendations for preventing retinopathy of prematurity (ROP) involves screening a large number of
patients. We performed a prospective study to establish a useful screening system for ROP prediction and we have
determined that measuring serum levels of IGF1 at week three and the presence of sepsis have a high predictive value for
the subsequent development of ROP. A total of 145 premature newborn, with birthweight ,1500 g and/or ,32 weeks
gestational age, were enrolled. 26.9% of them showed some form of retinopathy. A significant association was found
between the development of retinopathy and each of the following variables: early gestational age, low birthweight,
requiring mechanical ventilation, oxygen treatment, intracranial haemorrhage, sepsis during the first three weeks,
bronchopulmonary dysplasia, the need for erythrocyte transfusion, erythropoietin treatment, and low levels of serum IGF1
in the third week. A multiple logistic regression analysis was used to obtain curves for the probability of developing ROP,
based on the main factors linked with ROP, namely serum levels of IGF1 and presence of sepsis. Such preclinical screening
has the ability to identify patients with high-risk of developing retinopathy and should lead to better prediction for ROP,
while at the same time optimising the use of clinical resources, both human and material.
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Introduction
Retinopathy of prematurity (ROP) is a retinal vascular disease
affecting premature babies which, without early identification and
treatment, can lead to retinal detachment and loss of vision. ROP
is one of the main causes of blindness in premature babies [1],[2].
Multiple pathogenic factors have been identified for ROP.
Important among these are an association with blood oxygen
saturation and with infection [3],[4],[5],[6]. Recently, insulin-like
growth factor 1 (IGF1) has been shown to play a role in the
pathophysiology of this retinopathy. Specifically, a deficit of IGF1
in the first few weeks of post-natal life pre-dispose to non-
proliferative stages of the disease, while a subsequent increase in
IGF1 levels can lead to proliferative stages of ROP [7],[8],[9].
The necessity for early diagnosis and the establishment of a set
of clinical indications for laser photocoagulation treatment, which
reduces the incidence of retinal detachment and substantially
reduces morbidity in ROP, have led to recommendations by the
American Academy of Pediatrics with respect to ocular examina-
tion in premature babies [10],[11]. Thus, babies with a
birthweight of 1500 g or less, or gestational age of 32 weeks or
less, or birthweight between 1500 g and 2000 g, or more than 32
weeks, who either have an unstable clinical progression or who
require respiratory support, should all undergo ocular examina-
tion. Indications for treatment have been established in the
CRYO-ROP study [12] and for laser in the ETROP study [13].
Current guidelines include a large group of patients and the
beginning of examinations varies according to gestational age but
on average is between 4 and 6 weeks after birth. As this requires
not only the allocation of a dedicated team and significant
resources, but also the early identification of at-risk patients,
several screening methods have been developed, all of which are
based primarily on post-natal weight gain [14],[15],[16].
We have recently shown an important relationship between the
development of ROP and serum levels of IGF1 measured in the
3rd week after birth which thus constitute a biomarker for the
disease. Additionally, the association was strengthened in the
presence of neonatal infection in the first three weeks defined as
clinical, analytical and/or microbiological criteria [9].
The aim of the current study was to establish a method of
preclinical screening for ROP, in patients of less than 32 weeks
gestational age and/or birthweight of less than 1500 g, based on
the following criteria: serum IGF1 levels and/or presence of
clinical, analytical or microbiological sepsis in the 3rd week post-
partum, gestational age and birthweight.
Materials and Methods
We carried out a prospective study over a 5-year period (2006–
2011) on newborn premature babies of birthweight less than
1500 g and/or less than 32 weeks gestational age (as determined
by the Dubowitz/Ballard morphological maturation scoring
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system [17],[18],[19] in conjunction with the date of birth
estimated from the 12-week ultrasound).
157 in-patients meeting the above criteria were evaluated –first
74 were previously reported [9]-. The hospital is a tertiary referral
care centre for a population of 394,172 and the Neonatal Unit has
Level 3b status. After applying the following exclusion criteria a
total of 145 patients were recruited for the study: gestational age
less than 24 weeks, any congenital abnormality, death, or absence
of informed consent from the parents. The study was approved by
the Clinical Hospital of the University of Santiago de Compostela
Ethics Committee and a written informed consent was obtained
from the next of kin. In each patient included in the study, serum
level of insulin-like growth factor (IGF1) was measured in the third
week after birth -it was described that IGF1 levels at third week
have more sensitivity and specificity on detection ROP disease [9]-
. 1.2 ml of blood was obtained by peripheral venipuncture, serum
obtained by centrifugation and analysis carried out using an
enzyme-labelled chemiluminescent immunometric assay (IMMU-
LITE 2000 IGF-I, Siemens (R) Healthcare Diagnostics Ltd.,
Surrey, UK).
Other factors associated with ROP were also evaluated:
gestational age, morphometric data at birth, type of birth,
mechanical ventilation (type and duration), oxygen (fraction of
inspired oxygen (FiO2) and duration), sepsis in the first three
weeks, bronchopulmonary dysplasia, patent ductus arteriosus,
intracranial haemorrhage, need for erythrocyte transfusion or
treatment with erythropoietin (EPO).
The ocular examination was carried out by an ophthalmologist
trained specifically in the diagnosis of retinopathy of prematurity,
and performed between the 4th and 6th weeks post-partum or, if it
occurs previously, at 34 weeks of corrected gestational age. Ocular
examinations were continued until the patient was discharged by
the ophthalmologist.
Statistical analyses were carried out using the SPSSH 15.0
WindowsH program. Student’s t-test, U Mann-Whitney test and
the chi-squared test were used for quantitative (normalized or not)
and qualitative variables, respectively. A multiple logistic regres-
sion analysis was carried out on variables found to be associated
with ROP, and curves obtained to show the probability of
developing the disease. A two tailed ‘p’ value of less than 0.05 was
considered statistically significant.
Results
Of the 145 patients recruited to the study, 39 (26.9%) developed
some degree of ROP. Of these, 20 developed ROP stage 1
(51.3%), 12 stage 2 (30.8%) and 7 stage 3 (17.9%). 7 patients had
ROP-plus disease (17.9%). Photocoagulation treatment was
indicated only in 5 (12.8%) patients.
Measured variables are shown in Table 1. Patients who
developed ROP were of significatively lower gestational age and
birthweight, and shorter body length and cranial circumference at
birth. No significant differences were seen with respect to gender,
type of birth, antenatal steroid treatment, multiple birth or
necessity for treatment with surfactant.
A total of 109 patients required some form of respiratory
support. A significantly higher incidence of ROP was found in
patients receiving high-frequency oscillatory ventilation, and in
those ventilated for longer, either conventionally or non-invasively.
Oxygen administration, including longer-term and with a
higher FiO2, were also significantly correlated with the develop-
ment of ROP.
Table 1. Demographics and characteristics of enrolled
patients (mean 6 standard deviation).
ROP
No Yes p
Number of patients 106 39
Gestational age at birth (weeks) 30.9661.98 28.9962.02 0.000
Birthweight (g) 1361.176263.19 1094.056224.71 0.000
Length at birth (cm) 38.8762.67 36.7762.59 0.000
Cranial circumference at birth (cm) 27.5663.01 26.0161.91 0.000
Sex Female 56 (52.8%) 14 (35.9%) NS
Male 50 (41.2%) 25 (64.1%)
Type of
birth
Vaginal 24 (22.6%) 7 (17.9%) NS
Cesarean 82 (77.4%) 32 (82.1%)
Antenatal steroids 77 (72.6%) 25 (64.1%) NS
Multiple birth 37 (34.9%) 10 (25.6%) NS
Surfactant treatment 52 (49%) 23 (58.9%) NS
Mechanical ventilation 74 (69.8%) 35 (89.7%) 0.014
HFO 3 (2.8%) 6 (15.4%) 0.005
Conventional 43 (40.6%) 22 (56.4%) NS
Number of days 1.4163.76 3.8166.51 0.035
Non-invasive 70 (66.1%) 35 (89.7%) 0.005
Number of days 3.7665.13 11.31611.35 0.000
Oxygen administration 59 (55.7%) 32 (82.1%) 0.004
Number of days 5.1569.76 17.19622.63 0.003
Maximum FiO2 0.3160.14 0.3960.21 0.028
Intracranial haemorrhage 16 (15.1%) 16 (41%) 0.001
Sepsis (,3 weeks post-partum) 32 (30.2%) 30 (76.9%) 0.000
Patent ductus arteriosus 19 (17.9%) 12 (30.8%) NS
Bronchopulmonary dysplasia 10 (9.4%) 16 (41%) 0.000
Blood transfusion 13 (12.3%) 19 (48.7%) 0.000
EPO treatment 47 (44.3%) 27 (69.2%) 0.008
IGF1 (3rd week) 44.5614.93 28.9767.23 0.000
Abbreviations: FiO2: fraction of inspired oxygen; HFO: high-frequency oscillatory
ventilation.
doi:10.1371/journal.pone.0088781.t001
Table 2. IGF1 levels in the 3rd week of life according to
different clinical variables.
No Yes p
Mechanical ventilation 48.23615.41 37.79613.95 0.001
Oxygen administration 47.38617.11 36.27611.85 0.000
Intracranial haemorrhage 41.17614.85 37.57615.33 NS
Sepsis (,3 weeks post-partum) 45.30615.20 33.68611.80 0.000
Patent ductus arteriosus 42.80615.29 31.2169.22 0.000
Bronchopulmonary dysplasia 42.59615.15 29.8368.21 0.000
Blood transfusion 43.26615.02 29.9069.05 0.000
EPO treatment 46.45616.75 34.85610.52 0.000
doi:10.1371/journal.pone.0088781.t002
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Figure 1. IGF1 levels (Y-axes) dispersion at third week related with the weight gain (X-axes) in the first three weeks of life.
doi:10.1371/journal.pone.0088781.g001
Figure 2. Probability of Retinopathy of Prematurity as a function of IGF1 level and the presence or absence of sepsis in the first
three weeks post-partum.
doi:10.1371/journal.pone.0088781.g002
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A clear association was found between ROP and intracranial
haemorrhage, sepsis in the first three weeks, development of
bronchopulmonary dysplasia, and necessity for blood transfusion.
No relationship was found with patent ductus arteriosus.
Serum IGF1 measured in the third week post-partum was found
to be significantly lower in patients who developed ROP than
those who did not and to be independent of gestational age.
Also, IGF1 serum levels at third week of life were significantly
lower in those patients who developed bronchopulmonary
dysplasia, needed any kind of mechanical ventilation or oxygen
support, patent ductus arteriosus, sepsis in the first 3 weeks of life,
EPO treatment or needed transfusion. Although IGF1 level was
lower in patients with intracranial haemorrhage, it was not
significant (Table 2).
We evaluated the weight gain during the first 3 weeks of life and
was correlated with IGF1 levels at third week of life (Figure 1).
A multiple logistic regression analysis carried out on the
variables found by Student’s t-test to be significantly correlated
with development of ROP showed that only serum levels of IGF1
in the third week (p = 0.002) and presence of sepsis –considered as
clinical, analytical and/or microbiological- in the first three weeks
(p = 0.036) significantly increased the probability of developing
ROP (Table 3) (Figures 2–4).
The graphs obtained give the probability of developing ROP of
any stage with respect to serum IGF1 level in the third week post-
partum and presence or absence of sepsis in the first three weeks.
Further categorisation by gestational age and birthweight show a
greater probability of developing ROP with lower gestational age
and weight at birth.
Application of the described screening method to our studied
population gave ROC curves for the graphs of gestational age and
weight at birth with a discriminative efficiency for ROP diagnosis
of 86.9% CI95% (80.4%–93.5%) and 87.3% CI95% (81%–
93.6%), respectively. The ROC curves show a cut-off point of
30%. The screening method employed therefore gave a positive
result (high risk of developing ROP) if either graph (gestational age
or birthweight) showed a probability of ROP of more than 30%,
but a negative result (low risk of ROP) if the probability shown by
both graphs (gestational age and birthweight) was less than 30%.
This method allows discrimination between patients at risk of
developing ROP and those not at risk with a sensitivity (S) of
89.2%, specificity (E) of 76.7%, positive predictive value (PPV) of
57.9%, and negative predictive value (NPV) of 95.2%. If, for
example, the probability curves are applied to a patient of
birthweight over 1250 g and/or more than 30 weeks of gestational
age at birth, and a negative result is obtained, it is very likely that
the patient will not develop ROP (S 80%, E 96.4%, PPV 66.7%,
NPV 98.2%).
Discussion
We have developed a method for the prediction of retinopathy
of prematurity, based on serum levels of IGF1 in the third week
and the presence or absence of sepsis in the first three weeks after
birth. By sub-dividing the curves of probability of developing the
disease obtained, according to gestational age and weight at birth,
we have developed a highly discriminative and sensitive means of
prediction of ROP in a cohort of 145 newborn premature babies
of birthweight ,1500 g and/or , 32 weeks gestational age at
birth. The usefulness of our preclinical screening method is that it
has the ability to reduce the number of patients who would
otherwise undergo currently established routine screening, pre-
dicting with a high probability whether or not a patient is at risk of
developing the disease.
Therefore, the use of a preclinical screening method in
premature newborn patients should limit the number of full
ophthalmic retinal examinations, as well as making better use of
resources – human, technical and economic – while maintaining
the current indications for investigation of patients at high risk of
developing ROP.
It may be anticipated that universal examination of premature
babies of birthweight , 1250 g and/or gestational age at birth of
, 30 weeks, together with tailored investigations in individual at-
risk patients, identified principally using the screening curves such
as those that we have shown here, will optimise available resources
while at least maintaining current levels of identification and
treatment of ROP [20],[21],[22],[23],[24]. In the same context,
the most recent guidelines of the American Academy of
Paediatrics recommend the restriction of universal screening to
newborn babies of less than 30 weeks gestational age, although
maintaining the birthweight cut-off at 1500 g [11].
In the current study, applying our preclinical screening method
to patients of more than 1250 g and/or more than 30 weeks
gestational age has enabled us to show that a negative test result
(curves for gestational age and weight at birth both showing a
probability of developing ROP of less than 30%) has an accuracy
(NPV) of 98.2%. This high predictive value would mean that a
series of ophthalmic investigations could be substituted for a single
scan at 40 weeks of corrected gestational age that would serve as
validation and ensure the effectiveness of our preclinical screening
method.
Other published screening methods are based on post-natal
weight gain in premature neonates [14],[15],[16]. Studying IGF1
levels, by contrast, assumes that they give a better indication of the
status of the newborn, in terms not only of nutrition, since good
nutritional status and potnatal growth are associated with increases
in IGF1, but also several other factors such as the development of
sepsis, bronchopulmonary dysplasia, the need for erythrocyte
transfusion or EPO treatment, and all of which are associated with
diminished levels of IGF1. Because of these results, we think that
IGF1 is a good marker for the clinical status of the premature
baby. Lower IGF1 levels are associated to critical patients who
need erythrocyte transfusion, or respiratory support, or develop a
bronchopulmonary dysplasia or a patent ductus arteriosus, i.e.,
situations all related to the genesis of ROP. There are indeed,
premature babies with normal post-natal weight gain but low
levels of IGF1 who develop ROP. On the other hand, many
children have poor weight gain, high IGF1 level and do not
develop ROP. Also, other newborns have a great weight gain at
the expense of free water instead of lean mass which is not
correlated with an increasing level of IGF1. We therefore consider
that a screening system based on IGF1 levels results in a better
understanding of the true status of the patient.
Figure 3. Probability of Retinopathy of Prematurity as a function of IGF1 level, presence of sepsis (A) or not (B) in the first three
weeks post-partum and gestational age at birth.
doi:10.1371/journal.pone.0088781.g003
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Figure 4. Probability of Retinopathy of Prematurity as a function of IGF1 level, presence of sepsis (A) or not (B) in the first three
weeks post-partum and birthweight.
doi:10.1371/journal.pone.0088781.g004
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The other parameter that we have analysed and found to be
strongly correlated with the development of ROP is the presence
of sepsis in the first three weeks post-partum, as defined by clinical,
analytical or microbiological criteria [25]. The importance of
sepsis has previously been described [9], while the current study
shows that its combination with IGF1 levels increases the accuracy
of prediction of ROP.
The introduction to any particular hospital neonatal unit of a
screening method for ROP, with its corresponding reduction in
the number of criteria used to identify at-risk patients should be
accompanied by a validation study in which patients not deemed
to be at-risk are shown to have developed normal retinal
vascularisation by 40 weeks of corrected gestational age.
Conclusion
A full understanding of the incidence of ROP in any individual
neonatal unit and thus the appropriate introduction of an IGF1
screening method can be used to develop a rigorous and useful
system for the identification of high-risk patients. Preclinical
screening could reduce the number of patients undergoing
ophthalmic examination so lightening the burden on the
ophthalmological team and maintaining adequate levels of care
quality.
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9. Pérez-Muñuzuri A, Fernández-Lorenzo JR, Couce-Pico ML, Blanco-Teijeiro
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